Cigarette Smoking Decreases Global MicroRNA Expression in Human Alveolar Macrophages

Joel W. Graff1,2, Linda S. Powers1, Anne M. Dickson1, Jongkwang Kim1, Anna C. Reisetter1, Ihab H. Hassan1, Karol Kremens1, Thomas J. Gross1, Mary E. Wilson1,2,3,9, Martha M. Monick1,9

1 Department of Medicine, University of Iowa, Iowa City, Iowa, United States of America, 2 Iowa City Veteran Affairs Medical Center, Iowa City, Iowa, United States of America, 3 Department of Microbiology, University of Iowa, Iowa City, Iowa, United States of America

Abstract

Human alveolar macrophages are critical components of the innate immune system. Cigarette smoking-induced changes in alveolar macrophage gene expression are linked to reduced resistance to pulmonary infections and to the development of emphysema/COPD. We hypothesized that microRNAs (miRNAs) could control, in part, the unique messenger RNA (mRNA) expression profiles found in alveolar macrophages of cigarette smokers. Activation of macrophages with different stimuli in vitro leads to a diverse range of M1 (inflammatory) and M2 (anti-inflammatory) polarized phenotypes that are thought to mimic activated macrophages in distinct tissue environments. Microarray mRNA data indicated that smoking promoted an “inverse” M1 mRNA expression program, defined by decreased expression of M1-induced transcripts and increased expression of M1-repressed transcripts with fewer changes in M2-regulated transcripts. RT-PCR arrays identified altered expression of many miRNAs in alveolar macrophages of smokers and a decrease in global miRNA abundance. Stratification of human subjects suggested that the magnitude of the global decrease in miRNA abundance was associated with smoking history. We found that many of the miRNAs with reduced expression in alveolar macrophages of smokers were predicted to target mRNAs upregulated in alveolar macrophages of smokers. For example, miR-452 is predicted to target the transcript encoding MMP12, an important effector of smoking-related diseases. Experimental antagonism of miR-452 in differentiated monocytic cells resulted in increased expression of MMP12. The comprehensive mRNA and miRNA expression profiles described here provide insight into gene expression regulation that may underlie the adverse effects cigarette smoking has on alveolar macrophages.

Introduction

Cigarette smoking is a prominent risk factor for many respiratory diseases including emphysema/COPD, respiratory bronchiolitis, interstitial lung disease, and desquamative interstitial pneumonitis [1,2,3]. In fact, a correlation exists between alveolar macrophage numbers and the severity of COPD [4,5,6,7]. Aberrant gene expression in alveolar macrophages has been shown to alter the protease/anti-protease balance in the lung contributing to the development of emphysema [7,8,9,10]. Of particular importance in maintaining the optimal protease/anti-protease balance is expression of matrix metalloproteinase 12 (MMP12), a macrophage secreted enzyme that degrades elastin. The importance of alveolar macrophage-derived MMP12 in emphysema is well described [8,11].

Alveolar macrophages are essential immune effector cells in the lung with functions that include pathogen clearance and responses to inhaled environmental exposures [8,12,13,14,15,16]. Smoking causes alveolar macrophage defects in phagocytosis, responses to pathogen-associated molecular patterns, and microbicidal activity [17,18,19,20,21]. These defects compromise alveolar macrophage-mediated protection from infectious agents [22].

Macrophage gene expression programs are altered in response to local environmental cues. These changes may underlie the regulatory role macrophages play in many disease processes [23]. The use of polarizing stimuli to activate macrophages in vitro identified unique macrophage gene expression programs and the associated activation phenotypes. For example, exposure to inflammatory stimuli such as IFNγ and LPS polarizes macrophages toward an M1 activated phenotype that is associated with microbicidal activity [23]. Alternatively, macrophages can be polarized to a variety of M2 phenotypes after exposure to IL-4, immune complexes, IL-10, TGFβ, or steroids [24]. Depending on the stimulus, the M2 phenotypes are associated with many
activities including wound healing, immunosuppression, or production of cytokines promoting type 2 immune responses.

Transcriptional profiles of human alveolar macrophages directly isolated from nonsmokers and active smokers have shown that cigarette smoke exposure alters macrophage gene expression [1,2,25]. The pattern in alveolar macrophages from smokers has been suggested to reflect both suppression of M1-induced transcripts and increased expression of M2-induced transcripts [2]. The data shown here, partially replicates this finding, while proposing a new definition of the altered phenotype in smoker alveolar macrophages.

MicroRNAs (miRNAs) are small, noncoding RNAs that have an important regulatory role in gene expression programs [26,27,28]. Inhibition of translation and degradation of the miRNA-targeted transcripts occurs when a miRNA guides an RNA-induced silencing complex to the targeted transcript via miRNA:mRNA base pairing [29]. Each miRNA has the potential to repress the expression of hundreds of genes [30]. Expression profiling has identified miRNAs that have increased abundance in macrophages responding to inflammatory conditions [31,32,33,34,35,36]. Despite an incomplete understanding of all transcripts targeted by the inflammation-induced miRNAs, several are known to regulate components of important signaling pathways involved in macrophage gene expression [31,37,38,39,40].

An initial study on the effect of smoking on human miRNA expression was reported by Schembri et al [41]. They identified 28 differentially expressed miRNAs when comparing primary human bronchial airway epithelium of smokers and nonsmokers. The effect of smoking on miRNA expression in human alveolar macrophages is unknown. We hypothesized that miRNAs have a role in regulating the unique gene expression program in alveolar macrophages of cigarette smokers. We examined miRNA and mRNA expression in alveolar macrophage RNA from active smokers and nonsmokers. Microarray-derived miRNA expression profiles suggested that smoking is associated with an inverse M1-type gene expression pattern in alveolar macrophages. Expression analysis of miRNAs showed a smoking dose-dependent global repression of miRNAs in alveolar macrophages. Target prediction analyses revealed many examples of downregulated miRNAs in smokers that correlated with increased expression of predicted mRNA targets. In vitro experiments showed a direct link between low expression of miR-452 and increased expression of MMP12 mRNA. These results are consistent with the hypothesis that miRNAs play a role in regulating gene expression in alveolar macrophages of smokers, and possibly a corresponding role in disease pathogenesis.

Materials and Methods

Ethics Statement

All procedures and protocols described in this communication were approved by the University of Iowa Institutional Review Board. Written informed consent was obtained and all clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki.

Alveolar Macrophage Donors

Subjects were recruited from the community by the Iowa Institute for Clinical and Translational Science (ICTS) Clinical Core via advertisements and word-of-mouth. Inclusion criteria for case subjects required at least a 10 pack-year history of smoking, while the nonsmoker control subjects were self-reported never smokers. Subjects were excluded if they had any significant co-morbid conditions such as pregnancy or other acute or chronic disease such as pre-existing asthma, interstitial lung disease or cardiovascular disease. Subjects were also excluded if a baseline spirometry revealed the forced expiratory volume in the first second was less than 60% of the predicted value based on National Health and Nutrition Examination Survey III data set.

Cohort 1. The first cohort of alveolar macrophage donors consisted of 4 nonsmokers and 4 active smokers with 31 ± 14 pack-year histories. All subjects were Caucasian. The nonsmoker group had 3 males and 1 female with a mean group age of 26 ± 9 years. The smoker group had 2 males and 2 females with a mean group age of 51 ± 8 years.

Cohort 2. The second cohort included 4 nonsmokers and 4 smokers with 31 ± 3 pack-year histories. All subjects were Caucasian except for 1 African American in the smoker group. The nonsmoker group had 2 females and 2 males with a mean group age of 31 ± 6 years. The smoker group had 2 males and 2 females with a mean age of 47 ± 8 years.

Cohort 3. The third cohort included 4 nonsmokers, 4 light smokers (12 ± 2 pack-year histories), and 4 heavy smokers (33 ± 6 pack-year histories). All subjects were Caucasian except for 1 African American in each of the smoker groups. Each of the three groups had 2 male and 2 female donors. The mean age for the groups was 35 ± 12 years for the nonsmokers, 36 ± 7 years for the light smokers, and 51 ± 7 years for the heavy smokers.

Bronchoalveolar Lavage

After informed consent was obtained, subjects underwent standard flexible bronchoscopy [42]. Local anesthesia with lidocaine instillation into the upper airway was followed by bronchoalveolar lavage whereby 20 ml of normal saline was instilled into a tertiary bronchus up to five times in three different lung segments. The first collection out of five was discarded to avoid possible contamination with upper airway secretions or lidocaine. The remaining lavage was filtered through sterile gauze and centrifuged at 200 x g for 5 minutes to pellet cellular material. The resulting pellet was suspended in phosphate buffered saline (PBS) and centrifuged at 200 x g for 5 minutes. A sample of the cells were labeled with Wright stain and microscopically examined to determine the proportion of the cells that were macrophages [43,44,45,46]. Aliquots of 5 x 10^6 cells were stored at −80°C until RNA isolation procedure was performed. Cell yields from bronchoalveolar lavage in cohort 1 averaged 25 ± 3 x 10^6 cells for the nonsmokers and 67 ± 4 x 10^6 cells for the active smokers. In all three cohorts the procedure generated a relatively pure population of alveolar macrophages with fewer than 5% neutrophils or lymphocytes in the bronchoalveolar lavage fluid.

RNA Isolation

RNA was isolated from alveolar macrophages or PMA-differentiated THP-1 cells using the mirVana miRNA Isolation kit [Applied Biosystems (ABI)]. The quantity and quality of the RNA samples was assessed using an Experion Automated Electrophoresis Station (Bio-Rad). The RNA quality indicator was above 8 for all samples where values of greater than 8 indicate primarily intact RNA on a scale of 1–10. After preparation, RNA samples were stored at −80°C until use.

mRNA Expression Analysis

Measurements of genome-wide macrophage mRNA expression were conducted using the GeneChip Human Exon 1.0 ST Arrays (Affymetrix). Generation of labeled cDNA, hybridizations, and scanning of the microarray were performed under contract by the University of Iowa DNA facility. The resulting data were analyzed...
using the Partek Genomics Suite version 6.5 (Partek). The data were assessed for quality and subjected to robust multiarray averaging (RMA) normalization. The normalized data were then analyzed using an ANOVA model with linear contrasts to calculate p-values and smoker-to-nonsmoker expression ratios. The false discovery rate (FDR) step-up method [47] was applied to correct for multiple testing. The expression data has been deposited in NCBI Geo repository (GSE34517).

### miRNA Expression Analysis

RNA from alveolar macrophages of nonsmokers and active smokers was reverse transcribed with MultiScribe Reverse Transcriptase (ABI) using Megaplex Primers version 2.0 (ABI). Changes in miRNA expression was then determined using human TaqMan Low Density Arrays version 2.0 (ABI). Ct values calculated using SDS version 2.4 (ABI) were exported to the Partek Genomics Suite to calculate smoker-to-nonsmoker expression ratios. Principle component analysis (PCA) was performed using standard functions built in MATLAB software version 7.9 (MathWorks). This analysis identified a representative miRNA within each cluster with the highest Pearson correlation between its expression profile and the first principal component from our PCA analysis [48]. Cluster analysis was performed using Euclidean clustering algorithm (http://discover.nci.nih.gov/cimminer/).

### Validation of Changes in Individual miRNAs

Validation studies were performed using alveolar macrophage RNA collected from the initial array group (cohort 1) and a non-redundant sample set (cohort 2). Individual TaqMan MicroRNA Assays corresponding to assays including in the TLDA version 2.0 assays (ABI) were used to document abundance of the mature forms of three of the downregulated miRNAs. Briefly, 10 ng RNA was reversed transcribed with MultiScribe RT (ABI) using a miRNA-specific stem loop primer. Then, PCR with TaqMan Universal PCR Master Mix (ABI) was performed using miRNA-specific real time primers. Expression levels were defined as a ratio between the Ct values of the indicated miRNA and the endogenous control, RNU48.

### Table 1. 25 most upregulated mRNAs in alveolar macrophages of smokers.

| Gene   | Description                              | Fold Change | Smoker AMs | M1 | M2a |
|--------|------------------------------------------|-------------|------------|----|-----|
| PLA2G7 | phospholipase A2, group VII              | 9.85        | up         | down | down |
| SPP1   | secreted phosphoprotein 1 (osteonectin)  | 8.98        | up         | down | no change |
| CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 | 8.63        | up         | down | no change |
| ATP6VD2| ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d2 | 8.41        | up         | ND | ND |
| SLC7A11| solute carrier family 7, member 11 (xCT) | 6.36        | up         | down | down |
| MMP12  | matrix metalloproteinase 12 (macrophage elastase) | 5.83        | up         | up | up |
| FABP3  | fatty acid binding protein 3             | 5.39        | up         | down | no change |
| RPL15  | ribosomal protein L15                    | 5.18        | no change  | down | no change |
| FLT1   | fms-related tyrosine kinase 1 (VEGFR)    | 5.13        | up         | no change | no change |
| A2M    | alpha-2-macroglobulin                    | 4.36        | up         | no change | no change |
| UCHL1  | ubiquitin carboxyl-terminal esterase L1   | 3.79        | up         | no change | no change |
| S100B  | S100 calcium binding protein B           | 3.53        | up         | no change | up |
| CA2    | carbonic anhydrase II                    | 3.34        | up         | down | 0 |
| SLC16A6| solute carrier family 16, member 6 (monocarboxylic acid transporter) | 3.28        | up         | down | up |
| S5BP3  | single stranded DNA binding protein 3     | 3.25        | up         | no change | no change |
| TDRD9  | tudor domain containing 9                | 3.18        | up         | no change | no change |
| OR6N2  | olfactory receptor, family 6, subfamily N, member 2 | 3.15        | ND         | ND | ND |
| HIST1H2AJ| histone cluster 1, H2aj                   | 3.13        | no change  | ND | ND |
| C4orf18| chromosome 4 open reading frame 18 (DKFZp434L142) | 3.1         | up         | down | no change |
| DNASE2B| deoxyribonuclease II beta                | 3.07        | up         | no change | no change |
| SDC2   | syndecan 2                               | 3.07        | up         | down | up |
| MGST1  | microsomal glutathione S-transferase 1    | 3.03        | up         | up   | down |
| AGPAT9 | 1-acylglycerol-3-phosphate O-acyltransferase 9 | 2.91        | up         | down | down |
| TM7SF4 | transmembrane 7 superfamily member 4 (DCSTAMP) | 2.75        | up         | no change | no change |
| LIPA   | lipase A, lysosomal acid, cholesterol esterase | 2.71        | up         | down | no change |

*Change indicates smoker-to-nonsmoker expression ratio in alveolar macrophages from this study.

Expression change of indicated mRNA described by Woodruff et al [25] in analysis of alveolar macrophage smokers and nonsmokers (GEO dataset 1269).

Expression change of indicated mRNA described by Martinez et al [55] in analysis of monocyte-derived macrophages (MDMs) polarized toward M1 or M2a phenotypes relative to unstimulated MDMs (GEO datasets 2429 and 2430).

("up" indicates upregulation; "down" indicates downregulation; "no change" indicates no change and "ND" indicates not determined).

[doi:10.1371/journal.pone.0044066.t001]
Analysis of miRNA Target Prediction Expression

Using the Partek Genomics Suite software, each indicated miRNA was used to query the TargetScan [49] and MicroCosm [50] databases to identify predicted targets. The smoker-to-nonsmoker expression ratio and ANOVA-derived p-value of each predicted miRNA target were exported from the GeneChip Human Exon microarray results to an Excel spreadsheet (Microsoft). Excel was used to filter data by expression ratios and p-values.

Expression of Predicted Targets in miRNA Antagonist-transfected THP-1 Cells

THP-1 cells were maintained in RPMI 1640 (Gibco) supplemented with fetal bovine serum (10%; Gibco). Cells were incubated with PMA (5 ng/ml; Sigma-Aldrich) for 18 hours to induce differentiation toward a macrophage phenotype [51]. They were then transfected with the miR-452 or negative control mirVana miRNA Inhibitors (25 nM; ABI) using RNAiMAX (Invitrogen). RNA was purified from cell lysates collected at 24 hours post-transfection. Total RNA (300 ng) was reverse-transcribed to cDNA using iScript cDNA Synthesis kit (Bio-Rad). SYBR Green-based quantitative PCR reactions (BioRad) were performed as previously described [52]. Specificity of the amplification was confirmed using melting curve analysis. Expression levels were defined as a ratio between the threshold cycle (Ct) values of MMP12 or TM7SF4 and the endogenous control, HPRT. The primers (Integrated DNA Technologies) used in the PCR reactions were: MMP12, forward 5'-aggtggaatcctagcccatgcttt-3', reverse 5'-tcaggatttggcaagcgttggttc-3'; TM7SF4, forward 5'-tgaggatttgcttgggttc-3', reverse 5'-ataaagcattcctgcctc-3'; HPRT, forward 5'-ctattaactggtgcctgctgt-3', reverse 5'-actgctgaccaaggaagcaag-3'.

Results

Alveolar Macrophages from Smokers Displayed an “Inverse” M1 Gene Expression Profile

Cigarette smoking has been shown to alter the transcriptional profile of human alveolar macrophages in a consistent manner as

| Gene      | Description                                      | Fold Changea | Smoker AMs  | M1  | M2a  |
|-----------|--------------------------------------------------|--------------|-------------|-----|-----|
| CXCL11    | chemokine (C-X-C motif) ligand 11                | -13.14       | down        | up  | no change |
| CXCL9     | chemokine (C-X-C motif) ligand 9                 | -5.69        | down        | up  | no change |
| SLC19A3   | solute carrier family 19 (thiamine transporter) | -5.93        | down        | no change | no change |
| EMR1      | egf-like module containing, mucin-like, hormone receptor-like 1 (F4/80) | -5 | down | up | no change |
| CXCL10    | chemokine (C-X-C motif) ligand 10                | -4.97        | down        | up  | no change |
| PDGFD     | platelet derived growth factor D                | -4.65        | down        | no change | no change |
| IGF1      | insulin-like growth factor 1                    | -4.47        | down        | down | no change |
| GBP5      | guanylate binding protein 5                     | -4.03        | down        | up  | no change |
| OVCH1     | ovochymase 1                                    | -3.86        | ND          | ND  | ND  |
| C8B       | complement component 8, beta                    | -3.78        | down        | no change | no change |
| CD69      | CD69 molecule                                   | -3.61        | down        | no change | no change |
| WDR49     | WD repeat domain 49                             | -3.32        | ND          | ND  | ND  |
| TNFSF10   | tumor necrosis factor (ligand) superfamily, member 10 (TRAIL) | -3.27 | down | up | no change |
| IFI27     | interferon, alpha-inducible protein 27 (ISG12)  | -3.17        | down        | up  | up  |
| TRHDE     | thyrotropin-releasing hormone degrading enzyme   | -2.99        | down        | no change | no change |
| MYB       | v-myb myeloblastosis viral oncogene homolog      | -2.97        | down        | no change | no change |
| GZMA      | granzyme A                                      | -2.82        | no change   | up  | no change |
| CLDN6     | claudin 6                                       | -2.67        | no change   | no change | no change |
| ARHGAP24  | Rho GTPase activating protein 24                 | -2.64        | down        | no change | no change |
| RXFP2     | relaxin/insulin-like family peptide receptor 2   | -2.63        | no change   | ND  | ND  |
| TRPC6     | transient receptor potential cation channel, subfamily C, member 6 | -2.59 | down | no change | no change |
| KLRK1     | killer cell lectin-like receptor subfamily K, member 1 | -2.55 | no change | no change | no change |
| MS4A6A    | membrane-spanning 4-domains, subfamily A, member 6A | -2.54 | no change | down | no change |
| GBP3      | guanylate binding protein 3                     | -2.52        | no change   | up  | no change |
| ITIH5     | inter-alpha (globulin) inhibitor H5             | -2.52        | no change   | no change | no change |

aChange indicates smoker-to-nonsmoker expression ratio in alveolar macrophages from this study.

bExpression change of indicated mRNA described by Woodruff et al [25] in analysis of alveolar macrophage smokers and nonsmokers (GEO dataset 1269).

cExpression change of indicated mRNA described by Martinez et al [55] in analysis of monocyte-derived macrophages (MDMs) polarized toward M1 or M2a phenotypes relative to unstimulated MDMs (GEO datasets 2429 and 2430). (‘‘up’’ indicates upregulation; ‘‘down’’ indicates downregulation; ‘‘no change’’ indicates no change and ‘‘ND’’ indicates not determined).

doi:10.1371/journal.pone.0044066.t002
reported by two independent groups [1,2,25]. Prior to measuring miRNA expression in alveolar macrophages from four normal healthy subjects and four cigarette smokers (cohort 1), microarrays were performed to compare the transcriptional profile of these donors to previous reports.

Tables 1 and 2 display the most upregulated and downregulated miRNAs, respectively, with p-values <0.05 in alveolar macrophages from smokers compared to nonsmokers. These regulated genes were compared to an independent mRNA expression profiling study in alveolar macrophages from 15 smokers and 15 nonsmokers by Woodruff et al., summarized in the 4th column of Tables 1 and 2 ([25] and GEO dataset GDS1269). Results from our study were in strong agreement with this previous study. Most of the highly regulated miRNAs were similarly regulated in both studies and none of these miRNAs were regulated in the opposite direction (compare 3rd and 4th columns within Tables 1 and 2).

To further evaluate the extent to which the gene expression profile in alveolar macrophages from smokers contrasts with an M1 profile, the highly regulated miRNAs listed in Tables 1 and 2 were compared to results reported by Martinez et al [53] that described the transcriptional profile of unstimulated, M1-polarized (IFNγ- and LPS-treated), and M2a-polarized (IL-4 treated) macrophages (GEO datasets GDS2429 and GDS2430). The alveolar macrophages from smokers have an “inverse” M1 gene expression profile because not only were mRNAs that are upregulated in M1 macrophages downregulated in alveolar macrophages from smokers compared to nonsmokers, similar to the observations of Shaykhiev et al [2], but also miRNAs downregulated by M1 polarization were often upregulated in smoker alveolar macrophages (compare 3rd and 5th columns within Tables 1 and 2). Unlike the M1-regulated mRNAs, there was not any discernible correlation between miRNAs regulated in alveolar macrophages in response to cigarette smoking and mRNAs regulated in macrophages in response to in vitro M2a-polarizing conditions.

A global mRNA abundance increase was reported in lung tissue from a rat model of cigarette smoking [54]. Among the miRNAs with p-values <0.05, more transcripts were upregulated in smoker alveolar macrophages relative to nonsmoker alveolar macrophages when using a 2-fold change cut-off. Specifically, 70 miRNAs were upregulated and 48 miRNAs were downregulated. However, when assessing all miRNAs detected by the microarrays, there were approximately equal numbers of miRNAs with smoker-to-non-smoker expression ratios greater than 1 (51.2%) and less than 1 (48.8%) in the alveolar macrophage samples (Figure 1A) and the expression ratios of miRNAs commonly used as endogenous controls were each close to 1 (Figure 1B). While there were significant differences in expression of specific miRNAs, there was no apparent global shift in global mRNA levels in human alveolar macrophages of smokers and nonsmokers.

**Total miRNA Abundance is Reduced in Smoker Alveolar Macrophages**

To address our hypothesis that miRNAs have a role in maintaining the unique smoking-associated gene expression profile, we next obtained miRNA expression profiles. TaqMan Low Density Array (TLDA) assays were used to measure miRNA expression in the same RNA samples from alveolar macrophages of smokers and nonsmokers that had been used to analyze mRNA expression (cohort 1). TLDA assays use quantitative RT-PCR to specifically measure the abundance of 667 mature human miRNAs. The total miRNA abundance appeared to be lower in alveolar macrophages from cigarette smokers compared to nonsmokers, with a median expression ratio of 0.63. Therefore, the majority (75.7%) of miRNA smoker-to-nonsmoker expression ratios was less than 1 (Fig 2A). Interestingly, the general repression of miRNA expression in alveolar macrophages of cigarette smokers coincides with reports that cigarette smoke reduces overall miRNA expression in primary human epithelial cells [41] and in lung tissues of rats [54].

The expression of miRNAs was determined using a small nucleolar RNA, RNU46, as an endogenous control. Three other small nucleolar RNAs (RNU24, RNU43, and RNU44) were
Figure 2. Expression profiling indicates a global repression of total miRNA abundance in alveolar macrophages of cigarette smokers. Smoker-to-nonsmoker miRNA expression ratios were determined using RNA from alveolar macrophages as template in TaqMan Low Density Array v2.0 RT-qPCR assays (ABI). The endogenous control, RNU48, was used to normalize the data. The eight RNA samples used as template in
Figure 1 were also used in these TLDA assays (cohort 1). A) Smoker-to-nonsmoker expression ratios are represented by black circles in order from lowest to highest for the 481 detected miRNAs. The arrow indicates the point where miRNA expression ratios in smokers and nonsmokers = 1. B) The expression ratios are shown for three additional endogenous control options provided with the TLDA assay are shown. C) The expression ratios and p-values of the 481 detected miRNAs are shown using a volcano plot. The significantly upregulated (red) and downregulated (blue) miRNAs are indicated along with the endogenous controls (green). D) The 54 miRNAs with smokers-to-nonsmokers expression ratios greater than 2 are shown following principle component analysis (PCA) with MATLAB software. This analysis identified a representative miRNA within each cluster with the highest Pearson correlation between its expression profile and the first principal component from our PCA analysis. E) Clustering analysis of the 54 regulated miRNAs was performed using CLMminer based on JCI-values of the TLDA results. The 4 clusters identified by PCA are labeled. Upregulated miRNAs are designated by various shades of red and downregulated miRNAs by various shades of blue.

Table 3. miRNAs upregulated >2-fold in alveolar macrophages of smokers.

| miRNA       | miRNA Family | Polycistronic miRNA Precursor | Fold Change | p-value |
|-------------|--------------|--------------------------------|-------------|---------|
| miR-132*    | miR-132      | miR-132/212                    | 78.47       | 0.0002  |
| miR-139-3p  | N/A          | N/A                            | 52          | 0.0151  |
| miR-548c-3p | miR-548      | miR-548c/548z                  | 16.71       | 0.0357  |
| miR-211     | miR-204      | N/A                            | 15.77       | 0.0355  |
| miR-222*    | miR-221      | miR-221/222                    | 15.3        | 0.0082  |
| miR-222     | miR-221      | miR-221/222                    | 12.59       | 0.0005  |
| miR-222*    | miR-221      | miR-221/222                    | 5.77        | 0.009   |
| miR-132     | miR-132      | miR-132/212                    | 3.05        | 0.0017  |
| miR-212     | miR-132      | miR-132/212                    | 2.58        | 0.0102  |

doi:10.1371/journal.pone.0044066.t003
upregulated miRNA correlated with a global decrease in its predicted targets (data not shown). There were, however, many instances in which downregulated miRNAs correlated with increased expression of a subset of predicted targets (Table 5). There was only one upregulated miRNA family, miR-221, that was associated with a downregulated predicted target, IGF1.

Table 4. miRNAs downregulated >2-fold in alveolar macrophages of smokers.

| miRNA   | miRNA Family* | Polycistronic miRNA Precursorb | Fold Changec | p-value |
|---------|---------------|--------------------------------|--------------|---------|
| miR-452 | miR-452       | miR-224/miR-452                | -1030.3      | <0.001  |
| miR-129-3p | N/A           | N/A                            | -414.23      | 0.004   |
| miR-31  | N/A           | N/A                            | -326.38      | 0.005   |
| miR-34b*| miR-34        | miR-34b/miR-34c                | -96.89       | 0.037   |
| miR-210 | N/A           | N/A                            | -84.03       | 0.007   |
| miR-200b*| miR-8         | miR-200a/miR-200b/miR-429      | -71.68       | 0.002   |
| miR-150 | N/A           | N/A                            | -70.28       | 0.001   |
| miR-449a| miR-449       | miR-449a/miR-449b/miR-449c     | -49.46       | 0.018   |
| miR-200a| miR-8         | miR-200a/miR-200b/miR-429      | -45.64       | 0.011   |
| miR-10b | miR-10        | N/A                            | -42.63       | 0.005   |
| miR-449b| miR-449       | miR-449a/miR-449b/miR-449c     | -33.37       | 0.047   |
| miR-224 | miR-452       | miR-224/miR-452                | -32.41       | <0.001  |
| miR-708 | N/A           | N/A                            | -26.52       | <0.001  |
| let-7b* | let-7         | let-7a-3/let-7b/miR-4763       | -25.9        | 0.044   |
| miR-149 | N/A           | N/A                            | -17.34       | 0.019   |
| miR-187 | N/A           | N/A                            | -12.18       | 0.001   |
| miR-125a-5p| miR-125   | let-7e/miR-99b/miR-125a        | -7.64        | 0.001   |
| miR-130*| miR-130       | N/A                            | -6.56        | 0.035   |
| miR-363 | miR-363       | miR-106a-92 cluster            | -6.3         | 0.004   |
| miR-99a*| miR-99        | let-7c/miR-99a                 | -6.15        | 0.003   |
| miR-99b | miR-99        | let-7e/miR-99b/miR-125a        | -4.6         | 0.019   |
| miR-10a | miR-10        | N/A                            | -4.55        | 0.008   |
| miR-95  | miR-95        | N/A                            | -4.23        | 0.003   |
| miR-489 | N/A           | miR-489/miR-653                | -3.5         | 0.005   |
| miR-429 | miR-8         | miR-200a/miR-200b/miR-429      | -3.36        | 0.05    |
| miR-939 | N/A           | miR-1234                       | -3.15        | 0.045   |
| miR-642 | miR-642       | N/A                            | -3.11        | 0.04    |
| miR-99b*| miR-99        | let-7e/miR-99b/miR-125a        | -3.1         | 0.027   |
| miR-200b| miR-8         | miR-200a/miR-200b/miR-429      | -2.94        | 0.03    |
| let-7i* | let-7         | N/A                            | -2.87        | 0.023   |
| miR-99a| miR-99        | let-7c/miR-99a                 | -2.78        | 0.017   |
| miR-106b| miR-17        | miR-25/miR-93/miR-106b         | -2.78        | 0.033   |
| miR-100 | miR-99        | let-7a-2/miR-100               | -2.73        | 0.014   |
| miR-589 | N/A           | N/A                            | -2.65        | 0.022   |
| miR-15a*| miR-15        | miR-15a/miR-16-1               | -2.61        | 0.049   |
| miR-146b-3p| miR-146    | N/A                            | -2.49        | <0.001  |
| miR-125b| miR-125       | N/A                            | -2.48        | 0.008   |
| miR-601 | N/A           | N/A                            | -2.38        | 0.005   |
| miR-630 | N/A           | N/A                            | -2.34        | 0.025   |
| miR-146b-5p| miR-146    | N/A                            | -2.2         | 0.006   |
| miR-223*| N/A           | N/A                            | -2.18        | 0.037   |
| miR-454*| N/A           | N/A                            | -2.14        | 0.034   |
| miR-193b| miR-193       | miR-193b/miR-365a              | -2.07        | 0.043   |

*Family names as specified by miRBase release 18.

bClustered miRNAs described in miRBase release 18 were assumed to be polycistronic pri-miRNAs.

cFold change indicates miRNA expression in alveolar macrophages of smokers compared to nonsmokers.

doi:10.1371/journal.pone.0044066.t004
To test our hypothesis that miRNAs influence the mRNA expression profiles in alveolar macrophages of cigarette smokers, we evaluated whether antagonizing the function of a specific miRNA would lead to increased mRNA expression of the predicted target. We were particularly interested in whether the highly downregulated miRNA, miR-452, influenced the expression of MMP12, a protease relevant to smoking-related diseases that is highly upregulated in alveolar macrophages of smokers. Transfecting in an inhibitor of miR-452 resulted in elevated expression of MMP12 transcripts, but had no effect on another predicted target of miR-452, TM7SF4 (Figure 5).

**Discussion**

This study reports on miRNA and mRNA expression in alveolar macrophages from nonsmokers and active cigarette smokers. Significant differences in both miRNA and mRNA expression were found in alveolar macrophages obtained from nonsmokers and smokers. We identified a smoking history-
dependent decrease in global miRNA abundance. Importantly, we describe many examples of inverse relationships between miRNAs and their predicted mRNA targets and used an in vitro system to support our hypothesis that miRNAs influence the expression of an important macrophage product.

In vitro polarization of monocyte-derived macrophages (MDMs) leads to distinct phenotypes that have been categorized as M1, M2a, M2b, and M2c [24,55]. This classification system is useful, particularly in defining gene expression programs related to specific polarized phenotypes. However, the extent to which these phenotypes accurately depict macrophage phenotypes in vivo has been difficult to determine, partly because purification of human macrophages from the tissues in which they are embedded is usually not possible. Human alveolar macrophages are unique in this aspect since relatively pure populations can be obtained from bronchoalveolar lavage fluid. A consistent alteration in gene expression profiles of human alveolar macrophages from cigarette smokers compared to nonsmokers has been reported by two

---

**Figure 4. Expression profiling of a second data set indicates a global repression of total miRNA abundance in alveolar macrophages of cigarette smokers.** Nonsmoker, light smoker, and heavy smoker miRNA expression ratios were determined by TLDA assays using RNA from alveolar macrophages (cohort 3). The endogenous control, RNU48, was used to normalize the data. **A** Smoker-to-nonsmoker expression ratios are represented by black circles (light smokers) and red circles (heavy smokers) in order from lowest to highest for 277 and 281 detected miRNAs, respectively. **B** The number of miRNAs with a greater than 2-fold change between the two smoker groups and the nonsmokers are displayed. doi:10.1371/journal.pone.0044066.g004

---

**Table 5. Downregulated miRNAs in alveolar macrophages of smokers and corresponding predicted mRNA targets with upregulated expression.**

| miRNA | Predicted mRNA target* |
|-------|-------------------------|
| miR-95 | PRSS21 (M) |
| miR-99a | UGCG (M) |
| miR-99b | UGCG (M) |
| miR-100 | UGCG (M) |
| miR-106b | C10orf58 (M) |
| miR-125b | ATP13A3 (T), BCAT1 (T), C10orf58 (T), CSF (M), LIPA (T), TXNRD1 (T) |
| miR-130a | ATP13A3 (T), BCAT1 (T) |
| miR-187 | FAIM (M), MGST (M), UCHL1 (M) |
| miR-193b | GCLC (M), SLC16A6 (M & T) |
| miR-200b | CCDC102B (M), CYP1B1 (T), FLT1 (T) |
| miR-363 | SLC16A1 |
| miR-429 | ATP13A3 (M), CCDC102B (M), CSF1 (M), CYP1B1 (T), FLT1 (T), SDC2 (T) |
| miR-449 | C10orf48 (M), FABP3 (M), PRSS21 (M) |
| miR-449b | C10orf48 (M), FABP3 (M) |
| miR-452 | CCDC102B (M), GSR (M), **MMP12 (M)**, MOSPD1 (M), SPRY2 (M), TDRD9 (M), **TM7SF4 (M)**, C10orf58 (M), SLC7A11 (T) |
| miR-601 | CA2 (M) |
| miR-630 | C10orf48 (M), CA2 (M), PLA2G7 (M), SLC04C1 (T), SPRY2 (M) |
| miR-708 | CSF1 (T) |

*Gene symbols of putative miRNA targets with the prediction algorithm indicated within parenthesis ("M" = MicroCosm; "T" = TargetScan). Text in bold identifies genes tested in correlation assays (see Figure 5). doi:10.1371/journal.pone.0044066.t005
independent groups of investigators [1,2,25]. Despite a relatively small alveolar macrophage sample size, we were able to confirm a similar transcriptional expression profile with Woodruff et al [25].

The gene expression profile of smoker alveolar macrophages was recently described as a “deactivated M1 polarization program” [2]. We suggest that the gene expression program could best be described as an “inverse” M1 profile, because M1-induced mRNAs are less abundant and M1-repressed mRNAs were more abundant in alveolar macrophages of smokers relative to nonsmokers.

Since cigarette smoking is associated with increased risk of pulmonary infections [56], understanding the mechanisms causing the inverse M1 phenotype in smoker alveolar macrophages might provide therapeutic targets for improving antimicrobial activity. Generation of M1-polarized MDMs in vitro is accomplished by treatment with two stimuli, typically IFN\(\gamma\) and either TNF\(\alpha\) or another molecule that promotes TNF\(\alpha\) production such as LPS [23,55]. One possibility is that the inverse M1 phenotype described for smoker alveolar macrophages is due to a cigarette smoke-induced defect in TNF\(\alpha\)- and/or IFN\(\gamma\)-induced signaling such as the NF-\(\kappa\)B and JAK-STAT pathways. Indeed, impairment in IFN\(\gamma\) signaling has been described in alveolar macrophages and epithelial cells of cigarette smokers [57,58]. The mechanism responsible for impaired IFN\(\gamma\) signaling is unknown. Whether miRNAs play a role promoting the inverse M1 gene expression program is currently being investigated.

We hypothesized that miRNAs are at least partly responsible for regulating the unique gene expression profile in alveolar macrophages of smokers. The RNA samples collected from cohort 1 for miRNA expression profiling of smoker and nonsmoker alveolar macrophages were also used in TLDA miRNA profile assays to compare the abundance of 667 human miRNAs. This global approach to evaluating miRNA expression identified 54 miRNAs with significantly altered expression. Among the 10 miRNAs that were significantly upregulated by $2$-fold, 7 are located on two polycistronic pri-miRNAs, the miR-132/212 cluster and the miR-221/222 cluster.

Thus, increased transcription of these two polycistronic pri-miRNAs could explain almost all of the highly upregulated miRNAs in smoker alveolar macrophages. Similarly, transcriptional regulation may also be important for many of the significantly repressed miRNAs in smoker alveolar macrophages because ten downregulated miRNAs were processed from four polycistronic pri-miRNAs (miR-224/miR452, miR-200a/miR-200b/miR-129, miR-449a/miR-449b/miR-449c, and let-7c/miR-99b/miR-125a).

An important observation from the miRNA profiling experiments was that the majority of miRNAs with altered expression in alveolar macrophages of smokers compared to nonsmokers were downregulated. Functionally, this should lead to increased mRNA expression in targeted genes. Using both the TargetScan and MicroCosm target prediction algorithms to analyze the results from cohort 1, we found that 30 of the 70 statistically significant mRNAs upregulated by $2$-fold were putative targets of miRNAs that were significantly downregulated by $2$-fold. The most strongly downregulated miRNA in smokers, miR-452, had the most predicted targets with upregulated expression. In experiments utilizing a miR-452 inhibitor, we show that inhibition of this miRNA in differentiated THP-1 cells resulted in elevated MMP12 transcript expression.

It is likely that miRNAs are not the only mechanism that could contribute to the inverse M1 alveolar macrophage phenotype. For example, soluble TNF receptor type II is increased in the sputum of smokers with COPD [59] and in mouse models [60]. This likely sequesters TNF\(\alpha\) and dampens the effects of M1 polarizing stimuli. Furthermore, the transcript SPP1 (encoding osteopontin), is consistently highly upregulated in studies of smoker alveolar macrophages [1,2,25]. Osteopontin treatment of macrophages results in proteasome-mediated degradation of STAT1 [61,62].

There was a striking $50–60\%$ reduction in total miRNA abundance in alveolar macrophages of smokers relative to nonsmokers. Global repression of miRNA expression that was also noted using non-TLDA miRNA profiling platforms in epithelial cells of smokers and in lung tissue of rats in a model of cigarette smoking [81,54]. Furthermore, miRNA expression...
profiling in induced sputum of cigarette smokers and nonsmokers showed that the majority of differentially expressed miRNAs were downregulated [59], although the method of data analysis in this latter study prevented the authors from commenting on differences in global miRNA abundance between the two alveolar macrophage sample types.

The reduced global expression of miRNAs reported here in alveolar macrophages of smokers has also been reported for many cancers. For example, total miRNA abundance is lower in tumors and tumor-derived cell lines relative to corresponding normal tissue [63,64]. The initial studies of global miRNA repression in cancer noted that miRNAs encoding the miRNA processing machinery were not altered in cancer cells [64]. Likewise, we detected no statistically significant changes in alveolar macrophages of smokers for transcripts encoding Dicer, Drosha, Ago1, Ago2, DicerR8, TRBP, PACT, exportin-5, or GW182 (data not shown). The repression of miRNAs in cancer appears to be due to inefficient processing of primary miRNA transcripts [65]. The cigarette smoke-induced mechanism of global miRNA repression in alveolar macrophages may be due to a deficiency in miRNA processing as described for cancer, an enhancement of miRNA degradation, or changes in primary miRNA transcription. Studies are ongoing to address each of these possibilities.

References

1. Heguy A, O'Connor TP, Lustick K, Worgall S, Cieciuch A, et al. (2006) Gene expression profiles of human alveolar macrophages of phenotypically normal smokers and nonsmokers reveals a previously unrecognized subset of genes modulated by cigarette smoking. J Mol Med 84: 318–328.
2. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey BG, et al. (2009) Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 183: 2807–2813.
3. Vlahos R, Bozinovski S, Jones JE, Powell J, Gras J, et al. (2006) Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Physiol 290: 1293–1295.
4. Hogg JC, Chi F, Unokaparch S, Woods R, Elliott WM, et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645–2653.
5. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG (1995) Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 152: 1666–1672.
6. Baranzini SP, Shapiro SD, Panuwel RA (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22: 672–680.
7. Shapiro SD (1999) The macrophage in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 32: 367–372.
8. Henninger GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila I, et al. (2009) MMP12, lung function, and COPD in high-risk populations. N Engl J Med 361: 2599–2608.
9. Bitterman PB, Remund SL, Hunninghake GW, Crystal RG (1982) Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest 70: 806–822.
10. Bitterman PB, Wessels MD, Remund SL, Adelberg S, Crystal RG (1986) Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest 77: 700–708.
11. Houghton AM, Qinorto PA, Perkins DL, Kobayashi DK, Kelley DG, et al. (2006) Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 116: 753–759.
12. Venet A, Hance AJ, Saltini C, Robinson BW, Crystal RG (1985) Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis. J Clin Invest 75: 293–301.
13. Wert SE, Yoshida M, LeVine AM, Bagnoli M, Jorns T, et al. (2006) Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci U S A 97: 5972–5977.
14. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S (2006) Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 194: 1375–1384.
15. Chen H, Cosan MJ, Hasday JD, Vogel SN, Medvedev AE (2007) Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 179: 6107–6116.
16. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, et al. (2007) Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. American journal of respiratory and cellular and molecular biology 37: 748–755.
17. King TE, Jr, Savici D, Campbell PA (1985) Phagocytosis and killing of Listeria monocytogenes by alveolar macrophages: smokers versus nonsmokers. J Infect Dis 150: 1309–1316.
18. Russell RE, Thorley A, Culquint SV, Dodd S, Donnelly LE, et al. (2002) Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Physiol 283: L667–73.
19. Stampfl MR, Anderson GP (2009) How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 9: 357–384.
20. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nature Rev Immunol 8: 933–949.
21. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 nonmucosal phagocytes. Trends Immunol 23: 549–555.
22. Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, et al. (2005) A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med 172: 1383–1392.
23. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
24. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136: 215–233.
25. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835–840.
26. Djuricovic S, Nahvi A, Green R (2011) A parsimonious model for gene regulation by microRNAs. Science 331: 550–553.
27. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Nature 466: 835–840.
28. Stampfl MR, Anderson GP (2009) How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 9: 357–384.
29. Djuranovic S, Nahvi A, Green R (2011) A parsimonious model for gene regulation by microRNAs. Science 331: 550–553.
30. Lip LM, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769–773.
31. Taquone KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12461–12466.
32. Antrobuski A, Bopoulous D, Arranz A, Dosaki G, Schworer S, et al. (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31: 220–231.
33. O'Connell RM, Taquone KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104: 13001–13006.
34. Ruggiero T, Trabucchi M, De Santa F, Zupi S, Harfe BD, et al. (2009) LPS induces KH-type splicing regulatory protein-dependent processing of micro-
RNA-153 precursors in macrophages. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 23: 2898–2908.

35. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitruc CD, et al. (2007) Modulation of miR-153 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179: 5082–5089.

36. Tserel L, Rumel T, Ksamd K, Phlipa M, Balhoff D, et al. (2011) MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J Biol Chem 286: 26487–26495.

37. Lu LF, Boldin MP, Chaudhry A, Liu LL, Taganov KD, et al. (2010) Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142: 914–929.

38. Nahid MA, Pauley KM, Sato AH, Chan EK (2009) miR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY. J Biol Chem 284: 34590–34599.

39. O'Neil LA, Sheedy FJ, McCoy CE (2011) MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 11: 163–175.

40. Tang Y, Luo X, Gai H, Ni X, Yuan M, et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60: 1063–1073.

41. Schembri F, Sridhar S, Perdomo C, Gustafson AM, Zhang X, et al. (2009) MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci U S A 106: 2319–2324.

42. Reisetter AC, Sbounova LV, Baltrusaitis J, Powers L, Gupta A, et al. (2011) Induction of inflammasome-dependent pyroptosis by carbon black nanoparticles. J Biol Chem 286: 21844–21852.

43. Monick MM, Carter AB, Gudmundson G, Geist LJ, Hunninghake GW (1998) Changes in PKC isoforms in human alveolar macrophages compared with blood monocytes. Am J Physiol 275: L389–397.

44. Monick MM, Powers LS, Barrett CW, Hinde S, Ashare A, et al. (2008) MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. J Immunol 180: 7485–7496.

45. Monick MM, Powers LS, Gross TJ, Flaherty DM, Barrett CW, et al. (2006) Active ERK Contributes to Protein Translation by Preventing JNK-Dependent ubiquitin-dependent degradation of STAT1 in RAW264.7 murine macrophages. J Immunol 177: 1636–1645.

46. D'Hulst AI, Bracke KR, Maes T, De Bleecker JL, Pauwels RA, et al. (2006) Role of tumour necrosis factor-alpha receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 28: 102–112.

47. Dhillon NR, Murphy WJ, Filla MB, Crespo AJ, Latham HA, et al. (2009) Down modulation of IFN-gamma signaling in alveolar macrophages isolated from smokers. Toxicol Appl Pharmacol 237: 22–28.

48. Pottelberge GR, Mestdagh P, Bracke KR, Thas O, Durme YM, et al. (2011) MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 183: 986–990.

49. D'Hubli A I, Bracke KR, Maes T, De Bleecker JL, Pauwels RA, et al. (2006) Autophagy defect in smokers' alveolar macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4.

50. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154–158.

51. Tsuchiya S, Kobayashi Y, Goto Y, Okamura H, Nakar S, et al. (1982) Induction of maturation in cultured human mononcytic leukemia cells by a phorbol diester. Cancer Res 42: 1530–1536.

52. Hanerotot S, Monick MM (2011) Vitamin D effects on lung immunity and respiratory diseases. Vitamins and hormones 86: 217–237.

53. Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. Journal of immunology 177: 7303–7311.

54. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, et al. (2009) Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 23: 806–812.

55. Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. Frontiers in bioscience : a journal and virtual library 13: 453–461.

56. Stampfli MR, Anderson GP (2009) How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nature reviews Immunology 9: 377–384.

57. Modestov MA, Mancini JJ, El-Mahdy S, Look DC (2010) Inhibition of IFN-gamma-dependent antiviral airway epithelial defense by cigarette smoke. Respir Res 11: 64.

58. Tsuchiya S, Kobayashi Y, Goto Y, Okamura H, Nakar S, et al. (1982) Induction of maturation in cultured human mononcytic leukemia cells by a phorbol diester. Cancer Res 42: 1530–1536.